Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ##STR00001##

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ##STR00001##

The present invention includes novel compositions useful for preventing or treating an HIV-1 infection in a subject in need thereof. The present invention further includes a novel method of preventing or treating an HIV-1 infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.

The present invention includes novel compositions useful for preventing or treating an HIV-1 infection in a subject in need thereof. The present invention further includes a novel method of preventing or treating an HIV-1 infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.

Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.

Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.

Provided are a surface-modifying agent that enables production of a coating film that preserves transparency of a substrate while displaying high water repellency and excellent stain resistance, particularly in terms of wipeability of oil-based ink, and also an article for which the surface-modifying agent is used. The surface-modifying agent includes a triazine skeleton, a (meth)acrylate group bonded to the triazine skeleton via an urethane bond, and a perfluoropolyether chain bonded to the triazine skeleton.

Provided are a surface-modifying agent that enables production of a coating film that preserves transparency of a substrate while displaying high water repellency and excellent stain resistance, particularly in terms of wipeability of oil-based ink, and also an article for which the surface-modifying agent is used. The surface-modifying agent includes a triazine skeleton, a (meth)acrylate group bonded to the triazine skeleton via an urethane bond, and a perfluoropolyether chain bonded to the triazine skeleton.

The present invention provides a novel P2X.sub.3 and/or P2X.sub.2/3 receptor antagonist. A compound represented by the formula (I): ##STR00001##
wherein R.sup.a, R.sup.b and R.sup.c are, (a) R.sup.a and R.sup.b are taken together Z; and R.sup.c is a group represented by R.sup.1c; or (b) R.sup.b and R.sup.c are taken together to form a bond; and R.sup.a is a group represented by YR.sup.1a; R.sup.1a and R.sup.1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R.sup.2 and R.sup.3 are each independently substituted or unsubstituted aryl, etc.; R.sup.4a and R.sup.4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is N(R.sup.5), etc.; R.sup.5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; Y is O, etc.; Z is O, etc.; and n is an integer of 0 to 4.